Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.